explore -WSS

explore

author：hotspot 2025-08-26 10:54:19 - browse：57

Photo of an arrangement of aspirin pills — Patrick Sison/AP

Low-dose aspirin led to a reduction in liver fat among patients with metabolic-associated liver disease, a small study out of Boston found.

The clinical trial, led by Tracey Simon of Massachusetts General Hospital and Harvard Medical School, compared two groups of patients with metabolic dysfunction-associated steatotic liver disease, or MASLD. One group was given baby aspirin daily for six months, while the other received a placebo pill. At the end of the study period, the aspirin group had reduced hepatic fat content while the placebo group had higher fat buildup.

MASLD (formerly known as non-alcoholic fatty liver disease) is a growing health threat, with 1 in 3 Americans having a troublesome amount of fat in their liver. The lipid buildup feeds into a toxic cycle of inflammation, tissue damage and, ultimately, irreversible scarring.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

focus

WSS

STAT Summit: Ending the crisis of Black deaths in the U.S.

STAT Summit: The economic case for universal basic health care

HHS names first

How I ended up pumping milk in a bathroom stall at JPM 2024

DeSantis can now import cheaper drugs. But will Biden get credit?

New menopause drug shows promise in relief for hot flashes

focus

explore

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Smaller biotechs seek to piggyback on weight loss drug boom

Peter Hotez and the public health issue of online harassment

Caregivers of transplant patients call for more support, training

As demand for Covid shots wanes, Moderna seeks its next success

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Novavax promises a turnaround & Lilly roils the obesity market

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Jerome Adams on the need for new antivirals for Covid

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

focus

Idaho abortion case may prompt more restrictions in other states

JPM 2024: Verve Therapeutics looks to mainstream genome editing

STAT Summit: The economic case for universal basic health care

Risky weight loss products often used by teens globally, per study

Designating disabled people as health disparity population is crucial

STAT Summit: Meghan O’Rourke on making chronic illness visible

knowledge

focus

focus

hotspot